ESCO2 inhibits tumor metastasis via transcriptionally repressing MMP2 in colorectal cancer
Authors Guo XB, Huang B, Pan YH, Su SG, Li Y
Received 24 July 2018
Accepted for publication 15 October 2018
Published 22 November 2018 Volume 2018:10 Pages 6157—6166
Checked for plagiarism Yes
Review by Single-blind
Peer reviewer comments 2
Editor who approved publication: Dr Beicheng Sun
Xiong-Bo Guo,1,* Bin Huang,1,* Ying-Hua Pan,2 Shu-Guang Su,3 Yan Li3
1Department of General Surgery, Institute of Surgery Research, Daping Hospital, Army Medical University, Chongqing, China; 2Department of Rheumatology, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China; 3Department of Pathology, The Affiliated Hexian Memorial Hospital of Southern Medical University, Guangzhou, China
*These authors contributed equally to this work
Background: Establishment of cohesion 1 homolog 2 (ESCO2) plays important roles in the regulation of cohesion and genomic stability and has been implicated in human cancers. Yet, its clinical significance and biological function in colorectal cancer (CRC) are unknown.
Methods: The expression of ESCO2 was examined by quantitative real-time PCR, Western blot, and immunohistochemistry. The role of ESCO2 in the tumor metastasis of CRC and the related mechanisms were investigated using in vitro and in vivo models.
Results: In this study, we show that low expression of ESCO2 in CRC was closely correlated with lymphatic and distant metastasis. Patients with low ESCO2 expression experienced shorter overall survival and disease-free survival in two independent cohorts containing a total of 587 CRC cases. ESCO2 overexpression suppressed, whereas ESCO2 knockdown promoted cell migration in vitro and tumor metastasis in vivo via modulation of epithelial–mesenchymal transition (EMT) process. Mechanistically, ESCO2 inhibited the transcriptional activity of MMP2 promoter to downregulate its expression. Reexpression of MMP2 partially attenuated the ESCO2-mediated malignant phenotypes.
Conclusion: Collectively, our data suggest that ESCO2 serves as a potential prognostic factor and exerts antimetastatic activity in CRC.
Keywords: ESCO2, MMP2, EMT, metastasis, colorectal cancer
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]